Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-01-06

FDA Approved: FOSAPREPITANT — Supplemental Application (Fresenius Kabi USA, LLC)

View source ↗

Summary

FDA approved a supplemental application for Fosaprepitant from Fresenius Kabi USA, LLC under an ANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE)

Snippet

SUPPL AP for FOSAPREPITANT (FOSAPREPITANT)